Journal of Clinical Pharmacy and Therapeutics · 2007 · 48 citations · 31 references
MedicinePharmacokineticsPharmacologyClinical PharmacologyNeuropharmacologyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyCytochrome P450 InteractionsAntipsychotic PharmacokineticsCyp2d6 Drug MetabolismHigh-performance Liquid ChromatographyOral Antipsychotic TherapyPharmacokinetic ParametersRandomized Crossover DesignsRandomized Crossover TrialsRisperidone Therapy
BACKGROUND: Although cytochrome P450 (CYP) 2D6 is often thought to be the only CYP responsible for the metabolism of risperidone, many reports suggest that CYP3A may be involved too. Rifampin, a potent CYP3A inducer, has been known to markedly decrease plasma concentrations of various drugs, which are concomitantly administered during treatment. OBJECTIVE: To examine the effect of rifampin on plasma concentrations of a single oral dose of risperidone in healthy Thai male volunteers. METHODS: In an open, randomized two-phase crossover study, separated by a 2-week period, 10 healthy Thai male volunteers received a single oral dose of 4-mg risperidone alone or with 600 mg rifampin, orally once daily for 5 days. Serial blood samples were collected at specific time points for a 48-h period. Risperidone was measured in plasma using high performance liquid chromatography with ultraviolet detection. Pharmacokinetic parameters were determined by using non-compartmental analysis. RESULTS: Co-administration with 600-mg rifampin once daily for 5 days was associated with a significant decrease in risperidone area under the curve (AUC(0-48)) and maximal concentration (C(max)) by 72% (157 x 49 +/- 48 x 80 vs. 42 x 66 +/- 7 x 81 ng/L/h; P<0 x 01) and 50% (32 x 44 +/- 6 x 05 vs. 16 x 16 +/- 2 x 73 ng/mL; P<0 x 05), respectively when compared with risperidone alone. CONCLUSIONS: Rifampin when used concurrently with risperidone significantly decreases the plasma concentration of risperidone. Our results provide in vivo evidence of the involvement of CYP3A in the metabolism of risperidone, in addition to CYP2D6. Thus, co-administration of risperidone with CYP3A inducer(s), including rifampin should be recognized or avoided in clinical practice.
31
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Journal of the American Medical Association · 1909 · 7.9K citations · Full text
Tsutomu Shimada, Hiroshi Yamazaki, Mayumi Mimura et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 2.8K citations
Medicine, Biochemistry, Pharmacology +15
Drug Metabolism and Disposition
Basic & Clinical Pharmacology & Toxicology · 2014 · 2.5K citations
Risperidone in the treatment of schizophrenia
Stephen R. Marder, Richard C. Meibach · American Journal of Psychiatry · 1994 · 1.2K citations
Canadian Journal of Psychiatry
The Canadian Journal of Psychiatry · 1979 · 770 citations